SEC Form 4 · accession 0001209191-17-009966
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Blight
Officer — Chief Scientific Officer
Period of report
Feb 9, 2017
Accepted (ET)
Feb 13, 2017 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 9, 2017 | M | 67,586 | $22.13 | A | 144,144 | D | |
| Common StockF1,F2 | Feb 9, 2017 | S | 67,586 | $22.4067 | D | 76,558 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F3 | $22.13 | Feb 9, 2017 | M | 67,586 | D | — | Feb 14, 2017 | Common Stock | 67,586 | 0 | D |
Explanation of responses
- F1Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2017 on the expiration date reported within Table II unless exercised.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $22.25 to $23.05 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The shares subject to these options vested in installments and were fully vested on 1/01/2011.